{"title":"通过药物再利用探索三阴性乳腺癌管理的前沿策略。","authors":"Sandhya Chaudhary, Kalpana Rahate, Ritam Mondal, Rahul Kumar","doi":"10.2174/0115680266360882250702093727","DOIUrl":null,"url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is the most lethal kind of illness, causing the cancer to spread to other regions of the body and eventually resulting in death. The lack of licensed, targeted drugs that can completely eliminate TNBC is a challenge to the present level of therapeutic options. Developing novel uses for already-approved drugs expedites the lengthy and expensive process of creating new ones. Drug repositioning has been made possible by developments in cheminformatics, genomics, and systems biology. Here we provide what is presumably the first thorough taxonomy of approaches to in silico drug repurposing, classifying them into four categories: structure-based, data-mining-based, transcription signature-based, and physiological networksbased. The most relevant studies from preclinical and clinical contexts are highlighted in this review, which focusses on molecular processes and signalling pathways such as adrenergic receptor, androgen receptor, STAT3, nitric oxide (NO) synthase, or AXL. Its main objective is to repurpose existing medications for the treatment of TNBC. We also focus on repurposing and modifying medications that particularly target this cell type in order to combat metastases and recurrence linked to TNBC. The reason for this is that CSCs are very important and may play a major role in tumour aggressiveness and unfavourable clinical outcomes.</p>","PeriodicalId":11076,"journal":{"name":"Current topics in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.\",\"authors\":\"Sandhya Chaudhary, Kalpana Rahate, Ritam Mondal, Rahul Kumar\",\"doi\":\"10.2174/0115680266360882250702093727\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Triple-negative breast cancer (TNBC) is the most lethal kind of illness, causing the cancer to spread to other regions of the body and eventually resulting in death. The lack of licensed, targeted drugs that can completely eliminate TNBC is a challenge to the present level of therapeutic options. Developing novel uses for already-approved drugs expedites the lengthy and expensive process of creating new ones. Drug repositioning has been made possible by developments in cheminformatics, genomics, and systems biology. Here we provide what is presumably the first thorough taxonomy of approaches to in silico drug repurposing, classifying them into four categories: structure-based, data-mining-based, transcription signature-based, and physiological networksbased. The most relevant studies from preclinical and clinical contexts are highlighted in this review, which focusses on molecular processes and signalling pathways such as adrenergic receptor, androgen receptor, STAT3, nitric oxide (NO) synthase, or AXL. Its main objective is to repurpose existing medications for the treatment of TNBC. We also focus on repurposing and modifying medications that particularly target this cell type in order to combat metastases and recurrence linked to TNBC. The reason for this is that CSCs are very important and may play a major role in tumour aggressiveness and unfavourable clinical outcomes.</p>\",\"PeriodicalId\":11076,\"journal\":{\"name\":\"Current topics in medicinal chemistry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current topics in medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115680266360882250702093727\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680266360882250702093727","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.
Triple-negative breast cancer (TNBC) is the most lethal kind of illness, causing the cancer to spread to other regions of the body and eventually resulting in death. The lack of licensed, targeted drugs that can completely eliminate TNBC is a challenge to the present level of therapeutic options. Developing novel uses for already-approved drugs expedites the lengthy and expensive process of creating new ones. Drug repositioning has been made possible by developments in cheminformatics, genomics, and systems biology. Here we provide what is presumably the first thorough taxonomy of approaches to in silico drug repurposing, classifying them into four categories: structure-based, data-mining-based, transcription signature-based, and physiological networksbased. The most relevant studies from preclinical and clinical contexts are highlighted in this review, which focusses on molecular processes and signalling pathways such as adrenergic receptor, androgen receptor, STAT3, nitric oxide (NO) synthase, or AXL. Its main objective is to repurpose existing medications for the treatment of TNBC. We also focus on repurposing and modifying medications that particularly target this cell type in order to combat metastases and recurrence linked to TNBC. The reason for this is that CSCs are very important and may play a major role in tumour aggressiveness and unfavourable clinical outcomes.
期刊介绍:
Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.